Skip to content
Screener

Omeros OMER Investing Cash Flow

Investing Cash Flow at other companies

Immunome logo
ImmunomeIMNM
-$12.02M-336%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$40.68M-23.8%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$350.79M-903%
Annexon logo
AnnexonANNX
$27.06M-72.3%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$192.78M-730%
Vor Biopharma logo
Vor BiopharmaVOR
-$263.24M-114,351%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$958.97M+245%
P/S10.7×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Omeros’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:07 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001437749-26-016720
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from the sale and maturities of investments30,05039,300
Purchases of investments(1,316)(718)
Purchases of property and equipment(41)
Net cash provided by investing activities28,73438,541
Financing activities:
Exercise of stock options8,20863
Repayment of 2026 Notes(17,077)
Principal payments on OMIDRIA royalty obligation(4,670)(1,722)

Document

FAQ

What is Omeros's investing cash flow?
Omeros (OMER) reported investing cash flow of $28.73M in Q1 2026.
How has Omeros's investing cash flow changed year-over-year?
Omeros's investing cash flow decreased by 25.4% year-over-year, from $38.54M to $28.73M.
What is the long-term trend for Omeros's investing cash flow?
Over 2 years (2021 to 2025), Omeros's investing cash flow has grown at a -5.9% compound annual growth rate (CAGR), from $193.71M to $171.38M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Omeros's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude